Stock OXIS INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News OXIS International, Inc. Other OTC

Equities

US6918294025

End-of-day quote Other OTC
Other stock markets
- USD - Intraday chart for OXIS International, Inc.
05-21 Top Midday Decliners MT
05-21 GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Top Midday Decliners
MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants
MT
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
AQ
Top Premarket Gainers
MT
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results
AQ
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall
MT
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
AQ
LEADING PROXY ADVISORY FIRMS, ISS AND GLASS LEWIS, RECOMMEND GT BIOPHARMA STOCKHOLDERS VOTE 'FOR' ALL PROPOSED ITEMS AT THE UPCOMING SPECIAL MEETING OF STOCKHOLDERS
AQ
Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders
AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
AQ
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia
CI
GT BIOPHARMA PRESENTED POSITIVE PRECLINICAL DATA FOR GTB-5550, A NOVEL TRIKE MOLECULE FOR TARGETED PROSTATE CANCER TREATMENT DURING THE SOCIETY FOR IMMUNOTHERAPY OF CANCER 2023 ANNUAL MEETING
AQ
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
AQ
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting
CI
GT Biopharma Reports Third Quarter 2023 Financial Results
AQ
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
GT Biopharma : Failure to Satisfy Listing Rule - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GTBP Stock
  4. Stock
  5. News OXIS International, Inc.